Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.45    
    

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.R.F §§ 200.80(B)4 AND 240.24B-2 

EDB
COY-15-RISC/I218-1

S03/1-1609901 

31 October 2003

Ms B.
Lynne Parshall, J.D.

Director

Isis Pharmaceuticals Singapore Pte Ltd

c/o Isis Pharmaceuticals, Inc.

2292 Faraday Avenue

Carlsbad, CA 92008-7208

United States of America 

Dear
Lynne 

APPLICATION FOR INCENTIVES UNDER THE RESEARCH INCENTIVE SCHEME FOR COMPANIES (RISC)

1    This
is with reference to your application of 03/08/2003 and subsequent revisions for incentives under the Research Incentive Scheme for Companies (RISC). 

2    We
are pleased to inform you that the Economic Development Board (hereinafter called "the EDB") has agreed to provide a grant not exceeding [***] in total to
ISIS PHARMACEUTICALS SINGAPORE PTE LTD (hereinafter called "the Company") under the RISC for your project on the development of ISIS R&D and SARS Programs (hereinafter called the "Development
Project"), as described in your application. This grant shall be subject to the following conditions: 

        Project Implementation  

	(a)
	The
Company shall implement the Development Project as indicated in the Company's application dated 03/08/2003 and subsequent revisions. The terms of the "Proposed Isis Singapore
Program—1 September 2003" Term Sheet are accepted for this Development Project.

	(b)
	The
Development Project shall be carried out in 2 phases, where Phase One will be conducted in Isis Pharmaceuticals, Inc. facilities in the USA and Phase Two in
the Company's facilities in Singapore.

	(c)
	The
Company shall meet the project milestones, deliverables and headcount commitment for Phase One and Two as shown in  Annex 1. For Phase Two only, the Company shall not be obligated to
reimburse the EDB for any grants that the Company has received,
provided that the Company has made good faith efforts to substantially meet the milestones and deliverables as outlined in Annex 1.

        Supported Period  

	(d)
	The
Company shall complete the Development Project within the qualifying period, which shall be from 1 April 2003 to 31
August 2007. Specifically, the qualifying period for Phase One at Isis Pharmaceuticals, Inc.'s USA facilities shall be from 1
April 2003 to [***], and for Phase Two at the Company's R&D unit in Singapore (hereinafter referred to as "the R&D unit") will commence not later than
[***], and for a total period of 3 years until 31 August 2007. Only expenses incurred during this qualifying period will be
supported except 

that,
it is anticipated that some Phase Two expenses (e.g. salary of the lab manager, expenses, such as equipment, associated with setting up of the R&D unit) will be incurred and supported in
the effort to establish the R&D unit prior to the actual commencement of the Singapore facility. It is agreed that amortization of the equipment shall commence after the equipment is installed in the
R&D unit. Expenses incurred outside the qualifying period will not be supported except as described above. The qualifying period shall not be extended
to include any phases of the Development Project that were not originally included in the Company's application dated 03/08/2003. 

         Grant Support  

	(e)
	The
grant shall cover actual qualifying costs for manpower, R&D equipment & materials and selected miscellaneous costs incurred by the Company on the Development Project during
the qualifying period. The qualifying items of expenditures are listed below, but shall be subject to a total maximum grant of [***]. Virement of the grant from one cost
category to another shall be permitted so long as the amount of funds changed does not exceed [***] of the category from which the funds are removed or
[***] of the category into which funds are transferred. Virement of the grant from one cost category (manpower, equipment & material or professional services) to another
for amounts greater than those allowed shall be considered on a case-by-case basis and shall require the prior approval of the EDB, which shall not be unreasonably withheld.
Virement due to job title changes and changes in equipment are acceptable. Virement will not result in increase in grant funding.

	(i)
	Phase One
(carried out at Isis Pharmaceuticals, Inc.'s facilities in USA): 

	Cost Category
 
	 	Cost Items
	 	Approved Grant (S$)*
	 
	Manpower	 	 	 	 	 
	 	 	Salary (Foreign)	 	[***	]
	
Equipment & Material	
 	

 	
 	

 	
 
	 	 	Material / consumables	 	[***	]
	
Professional services	
 	

 	
 	

 	
 
	 	 	Subcontract (Foreign)	 	[***	]
	
	 
	Subtotal (Phase One)	 	[***	]
	
	 

	(ii)
	Phase Two
(carried out at the Company's R&D unit in Singapore) 

	Cost Category
 
	 	Cost Items
	 	Approved Grant (S$)*
	 
	Manpower	 	 	 	 	 
	 	 	Salary (Local)	 	[***	]
	 	 	Airfare	 	[***	]
	 	 	Cost of living allowance	 	[***	]
	 	 	Training	 	[***	]
	
Equipment & Material	
 	

 	
 	

 	
 
	 	 	Equipment	 	[***	]
	 	 	Material / consumables	 	[***	]
	
Professional services	
 	

 	
 	

 	
 
	 	 	Subcontract (Local)	 	[***	]
	 	 	Subcontract (Foreign)	 	[***	]
	
	 
	 Subtotal (Phase Two)	 	[***	]
	
	 
	 Total Approved Grant (Phase One + Phase Two)	 	[***	]
	
	 

*
Please see Annex 2 for details on qualifying costs. 

	(f)
	The
qualifying cost for equipment (less its residual value, if any), is pro-rated based on the number of months equipment is used for the Development Project (this refers
to the date of delivery to the end of qualifying period) over approved useful life of equipment (please see Annex 2). The useful life of
equipment is as defined in the RISC grant application by the Company. 

	Qualifying Cost =	 	(Actual Expenses - Residual value)	 	×	 	No. of months equipment is used for the project
 Approved useful life of equipment

	(g)
	All
equipment supported under this RISC grant shall be used exclusively for the Development Project. The Company shall not sell, dispose or otherwise transfer the R&D equipment to
another party during the execution of the Development project without first obtaining the written approval of the EDB, which if so granted, shall be on such terms as the EDB deems fit. The Company
shall at all times maintain proper records with respect to the assets acquired through the grant.

	(h)
	The
Company shall not seek or receive funds from any other incentives offered by other agencies of the Government of Singapore for funding of this Development Project.

	(i)
	All
grant monies received shall be used solely for the implementation of this Development project. 

         Disbursements for Phase One  

	(j)
	The
3 Phase One payments of [***] each are triggered by:

	(i)
	Completion
of [***]

	(ii)
	Completion
of [***]

	(iii)
	Completion
of [***] 

Payments
will be made within [***] working days after receipt of the complete claim documents by the EDB. If the claims have raised a question or concern, the EDB shall inform
the Company in writing within such [***] working day period, specifying such question or concern. In such event, the [***] day working time limit shall
cease to run and shall resume when the question or concern has been resolved. 

        Disbursements for Phase Two  

	(k)
	Disbursements
may be made on a reimbursement basis upon application by the Company at quarterly intervals, subject to the fulfillment of paragraph 2(s) condition (1). Claims
must be submitted using the prescribed Form 1a and 1b and shall be certified by the Company's Vice President of Finance and the Principal
Investigator. The amount disbursed shall be based on the qualifying component of actual costs incurred. 

The
grant will be disbursed as follows: 

	(i)
	Disbursements
of up to a cumulative total [***]% of the approved grant amount shall be made upon application by the Company.

	(ii)
	The
remaining [***]% of the grant may be released upon application by the Company on completion of the Development Project.

	(l)
	For
all claims (except for the final claim), the first [***]% of the amount claimed will be disbursed to the Company upon receipt of claim and the remaining
[***]% will be disbursed upon the completion of checks, which in any event must be completed within [***]working days after receipt of the complete
claim documents, and provided that the Company has been making regular quarterly claims so that any one claim is not unusually large which would require a protracted checking period to process. If the
checks have raised a question or 

concern,
the EDB shall inform the Company in writing within such [***] working day period, specifying such question or concern. In such event, the [***]
day working time limit shall cease to run and shall resume when the question or concern has been resolved. 

	(m)
	The
final claim must be submitted within [***] months with complete documentation from the date of the offer
letter / from the end of the development period (31 August 2007), failing which any claim will be disqualified. 

        Submission of Auditor's Statements & Progress Reports  

         Auditor's Statements  

	(n)
	For total approved grant exceeding [***], all claims must be externally audited. This applies to the claims for  Phase Two of the
Development Project only. (The EDB has waived the requirement for external auditors' certifications of
ISIS USA Phase One claims of [***].) The audited statement of accounts shall be submitted on an annual basis, as well as
when the Development Project is completed or terminated. The wording of the audited statement should follow the prescribed format in Annex 6. The
Company shall make available to its auditor this Letter of Offer and its accompanying annexes as well as the attached Terms of Reference for the External Auditor per  Annex 7. The Company shall
ensure that the external auditor forwards a copy of the audited accounts directly to the EDB upon completion of the
audit. In the event that the external auditor cannot issue an unqualified report, the EDB shall have direct access to the external auditor to gather details with regard to the audit findings. 

         Progress Reports/Final Report  

	(o)
	The
Company shall submit progress reports to the EDB after each milestone completion for Phase One, and at half-yearly intervals for
Phase Two, in accordance with the prescribed format in Annex 8. The disbursement of any grant shall be subject to
the Company achieving the project milestones as stated in Paragraph 2(j) above and Annex 1. The final report is to be submitted upon full completion of the project. 

         Project Management & Co-ordination  

	(p)
	The
Company shall appoint a person (hereinafter called the "Principal Investigator") to lead the Development Project. The Principal Investigator shall be responsible for the proper
management, co-ordination and progress of the Development Project, the management of grants disbursed and all other matters pertaining to the Development Project, including the preparation
of claims, submission of audited statements and progress reports.

	(q)
	The
Principal Investigator shall be deemed as an agent of the Company throughout the Development Project and the EDB shall at all times have access to the Principal Investigator with
regards to all matters pertaining to the Development Project.

	(r)
	The
Company shall inform the EDB in writing of any change in the Principal Investigator. 

        Other Conditions  

	(s)
	This
RISC grant is also subjected to the following conditions:

	(1)
	Isis
Pharmaceuticals, Inc. will set up the Company's R&D unit and commence implementation of Phase Two of the Development Project no later than
[***] or within [***] days of lab space availability, whichever is later.

	(2)
	In
the event of successful commercialization of the SARS drug candidate(s) by Isis Pharmaceuticals, Inc., the Company or through 3rd party
licensing, EDB will recoup [***], either via a percentage of sales or royalties (not exceeding [***]. 

	(3)
	Both
Isis Pharmaceuticals, Inc. and the EDB intend that Isis Pharmaceuticals, Inc. will establish the Company's R&D unit as per paragraph 2(s)
condition (1) above. Both Isis Pharmaceuticals, Inc. and the EDB agree to certain remedies in the case that Isis Pharmaceuticals, Inc. fails to establish the Company's R&D unit
either through its own decision or due to the failure of the EDB to provide the agreed-to fully fitted out laboratory space. These remedies are described as follows:

	i.
	If
the EDB fails to make available the agreed-to fully fitted out laboratory space by [***], Isis Pharmaceuticals, Inc. or the
Company will have no obligation to [***]. Even in this event, Isis Pharmaceuticals, Inc. remains committed to establish the Company's R&D unit as soon as practically
possible.

	ii.
	If
Isis Pharmaceuticals, Inc. decides on its own to not proceed with establishing the Company's R&D unit even if the EDB has met its obligation to make fully
fitted out laboratory space available, Isis Pharmaceuticals, Inc. agrees to either repay [***] to the EDB or provide to the EDB up to [***] times
the actual grant provided to Isis Pharmaceuticals, Inc. or the Company [***] via a percentage of sales or royalties (not exceeding [***]) in the
event of successful commercialization of the SARS drug candidate(s). The selection of the repayment mechanism is at the choice of the EDB.

	(4)
	If
Isis Pharmaceuticals, Inc. or the Company (as the case may be) decides to [***], on terms to be negotiated at that stage

	(5)
	If
no additional partners participate in funding the SARS drug(s), the [***]

	(6)
	If
additional partners are involved in funding, EDB or its Designee shall receive rights of negotiation and terms for Asia-Pacific (including Japan) that are
comparable to the other partners.

	(7)
	Isis
Pharmaceuticals, Inc. will recruit and initiate training of at least [***] Isis Singapore researcher to lead the Company's operation
in Singapore no later than [***].

	(8)
	The
manager/head of the Company will be employed by Isis Pharmaceuticals, Inc. and will devote [***] of his time for the Company's
activities and spend approximately [***]% of his time in the USA

	(9)
	Isis
Pharmaceuticals, Inc. will recruit and initiate training of at least [***] researchers for the Company during 2004

	(10)
	The
Company will hire at least [***] full time employees (FTEs) in total (including [***] PhDs) no later than the end of
2005.

	(11)
	The
Company will incur total cumulative research spending of at least [***]) (inclusive of EDB's grant support) by the
[***] anniversary of the establishment of the Company's R&D unit.

	(12)
	The
Company will undertake at least [***] disease programs besides SARS

	(13)
	The
Company will screen, identify and develop at least [***] SARS drug candidate up to [***] by the
[***]anniversary of the establishment of the R&D unit.

	(14)
	If
Isis Pharmaceuticals, Inc. decides to spin-off or out-license drug candidate(s) arising from the Company, Isis
Pharmaceuticals, Inc. will [***.]

	(t)
	Isis
Pharmaceuticals, Inc. and the Company shall permit EDB officers to inspect the premises where the development work is carried out, all accounts on the development
expenditures and all records on the progress of the Development Project.

	(u)
	The
Company shall be required to provide, through responses to surveys or any other such studies carried out by the EDB, relevant information on the Development Project, as and when
requested by the EDB subject to limitations of company confidential information and all 

legal
requirements and limitations concerning disclosure of confidential information considered to be material by the corporation. 

3    In
the event the Project is aborted, the Company is to inform EDB in writing immediately. 

4    The
EDB reserves the right to recover from the Company the total amount of grant disbursed to the Company in Phase Two in any calendar quarter for any breach of condition under
which the RISC grant was approved. Prior to the recovery of the grant, the EDB will meet with the Company to discuss the matter. The parties will attempt to reach a solution that is mutually
acceptable. If the parties are unable to arrive at a mutually acceptable solution, the EDB shall have the final decision on the matter. 

5    The
Company shall keep the terms and conditions of this RISC grant confidential. Such information shall not be released to any external party, the public or the press unless prior
written consent from the EDB is given. Notwithstanding the foregoing, the Company shall be allowed to disclose the RISC grant information to the US Government and regulatory bodies when it is mandated
by law. Where disclosures have to be made available to the public or the company's shareholders, the extent of such disclosure shall not extend to actual financial support granted to the company.
Nevertheless, where it is mandated by law that the actual financial support amounts be disclosed to the shareholders of the company, the company undertakes to reasonably ensure that the recipients of
such information are aware of the confidential and sensitive nature of such information and to take the necessary precautions against information leakage. 

6    The
EDB reserves the right to change the terms and conditions of this offer from time to time as may be specified and deemed necessary by the EDB. 

7    If
you are prepared to accept this offer of a grant under the conditions stipulated above, please sign the acceptance letter attached and return it to EDB within  1 month from the date of this letter,
failing which this offer shall be deemed to have lapsed. 

8    If
you have any queries, please contact Ms Tricia Huang at (65)-6832-6856. For queries on claims, please call the EDAS hotline at
(65)-6832-6416. We wish you every success in this project. 

Yours
sincerely 

/s/  BEH SWAN GIN      

DR
BEH SWAN GIN

DIRECTOR

BIOMEDICAL SCIENCES 

Enc 

Enclosures: 

Acceptance
Letter 

	Annex 1	 	Project Milestones and Deliverables
	

Annex 2	
 	

Details on Qualifying Costs
	

Annex 3	
 	

Submission of Claim Forms and Reports
	 	 	Form 1 a—Fund Request
	 	 	Form 1 b—Breakdown of Fund Request
	 	 	Form 1 c—Interbank Giro Form
	

Annex 4	
 	

Explanatory Notes on Qualifying Costs Categories for Research Incentive Scheme for Companies
	

Annex 4A	
 	

Checklist of commonly made errors
	

Annex 5	
 	

Sample Fund Request
	

Annex 6	
 	

Format for External Auditor's Statement
	

Annex 7	
 	

Terms of Reference for External Auditors
	

Annex 8	
 	

Format for Project Progress and Final Report

EDB COY-15-RISC/I218-1

S03/1-1609901 

Date
: 

Chairman

Economic Development Board

250 North Bridge Road

#24-00 Raffles City Tower

Singapore 179101 

Attention:
Dr Beh Swan Gin 

ACCEPTANCE OF GRANT AWARD UNDER THE RESEARCH INCENTIVE SCHEME FOR COMPANIES  

	1
	I
refer to your letter of offer dated 31 October 2003.

	2
	I
confirm that my company will be undertaking the development project as submitted to the Board dated 03/08/2003 and subsequent revisions and that we accept the award of your grant not
exceeding [***] in aggregate, subject to the terms and conditions set out in the above mentioned letter of offer.

	3
	We
understand the need for EDB to ensure good governance of public fund and hence will do our utmost diligence in ensuring that all claims for reimbursement of project expenditure are
true and correct and all offer letter terms and conditions are complied with. 

	Signature	 	:	 	 
	 	 	 	 	
 Stanley Crooke, Chairman of the Board, President and CEO
	

Signature	
 	

:	
 	

 
	 	 	 	 	
 Lynne Parshall, Director, EVP & CFO
	

Company Stamp	
 	

:	
 	

 
	 	 	 	 	
 ISIS Pharmaceuticals
	

Date	
 	

:	
 	

 
	 	 	 	 	

Annex 1  

[***] 

Annex 2  

[***] 

Annex 3  

SUBMISSION OF CLAIM FORMS & REPORTS FOR RISC GRANTS  

	Claims	 	 	 	 
	

Quarterly	
 	

—	
 	

Form 1a—Fund Request

Form 1b—Breakdown of Fund Request

Form 1c—Interbank Giro Form*
	

Yearly	
 	

—	
 	

Statement from Coy's external auditor

(ref. Sample statement in Annex 6)

*
To be submitted together with the first fund request. However, this is not necessary if you have already submitted the application to EDB earlier and there is no change in the bank details. 

	

 	
 	

 	
 	

 
	

Report Submission	
 	

 	
 	

 
	

Half-Yearly	

 	

—	

 	

Project Progress Report

(ref. Annex 8)
	

End of Project	
 	

—	
 	

Project Final Report

(ref. Annex 8)

Form 1a  

[***]

Form 1b  

[***]

Form 1c  

APPLICATION FORM FOR INTERBANK GIRO

Please complete Part A and get your bank to complete Part B before returning the ORIGINAL

copy to the following address  

ECONOMIC DEVELOPMENT BOARD

250 North Bridge Road #18-00

Raffles City Tower

Singapore 179101

Attention:

PART A (TO BE COMPLETED BY VENDOR)  

	1.	 	Our bank details are as follows:	 	 
	 	 	 	 	

	 	 	Account Name	 	 
	 	 	 	 	

	 	 	Account Number	 	 
	 	 	 	 	

	 	 	Bank Name and Branch	 	 
	 	 	 	 	

	 	 	Bank Code and Branch Code	 	 
	 	 	 	 	

	2.	 	We authorise ECONOMIC DEVELOPMENT BOARD to credit all monies due to us this bank account. Amounts so discharged would constitute valid discharge of obligations due to us. This authorisation shall continue to be in force
until we have revoked it by notice in writing delivered to you.
	

3.	
 	

In the event of a change of bank account, we shall inform you in writing 30 days in advance before the change.
	Signature of Authorised Personnel	 	 
	 	 	 	 	

	Name and Designation	 	 
	 	 	 	 	

	Company Stamp	 	 
	 	 	 	 	

	Tel No and Fax No	 	 
	 	 	 	 	

	Date	 	 
	 	 	 	 	

	PART A (TO BE COMPLETED BY VENDOR'S BANK)
	We certify that the bank details and the signatures affixed in PART A are correct and consistent with our records. Please initial against any amendments to the information contained in Part A.
	Signature of Authorised Personnel	 	 
	 	 	 	 	

	Name and Designation	 	 
	 	 	 	 	

	Bank Stamp	 	 
	 	 	 	 	

	Tel No and Fax No	 	 
	 	 	 	 	

	Date	 	 
	 	 	 	 	

[***]

*
Related parties will include all subsidiaries, associates and the parent company, as well as all parties defined by SAS 21 on Related Party Disclosures. 

Annex 4  

[***]

Annex 4A  

[***]

Annex 5  

[***]

Annex 6  

Format for External Auditor's Statement  

The
Managing Director

Economic Development Board

250 North Bridge Road

#24-00 Raffles City Tower

Singapore 179101 

We
have performed the procedures as per the Terms of Reference on the Statement of Expenditure incurred by                        
(name of company). This is in connection with the development of
                        (project name or description and reference number) under
the                        (name of grant/scheme) of the Economic Development Board ("EDB") for the qualifying period from
                        (date) to            (date). Our engagement
was undertaken in accordance with the Singapore Standard on Auditing applicable to agreed upon procedure engagements.
 

The
procedures were performed solely to assist you in evaluating whether the amounts shown on the attached statement are in accordance with the documents and records kept by the Company and whether
those amounts have been included in accordance with the terms and conditions specified by the EDB in their Offer Letter
dated                        (and Supplemental Offer Letters
dated            )*. 

We
report our findings below: 

	(a)
	With
respect to item 1 of the Terms of Reference, we found no exceptions for procedures (a) to (h), and ensured that such procedures cover at least 85% of the value claimed in
the statement.

	(b)
	With
respect to item 2 of the Terms of Reference, we found that related party claims are excluded from item categories that prohibit related party transactions.

	(c)
	With
respect to item 3 of the Terms of Reference, we found no sale/lease/transfer/disposal of equipment that is funded by EDB during the execution of the project.

	(d)
	With
respect to item 4 of the Terms of Reference, we found no going concern issues based on the latest audit report of the company 

(Detail the exceptions if any)  

Our
report is solely for the purpose set forth in the second paragraph of this report and for your information, and is not to be used for any other purpose or to be distributed to any other parties.
This report relates only to the accounts and items specified above and does not extend to any financial statements of            (name of company), taken as a whole. 

	 	 	 	 	 	 	 	 	(firm)
	 	 	 	 	 	 	
	 	 
	 	 	 	 	 	 	Certified Public Accountants
	

Singapore	
 	

 	
 	

 	
 	

 	
 	

 
	

 	
 	

(date)	
 	

 	
 	

 	
 	

 
	
	 	 	 	 	 	 	 	 

Annex 7  

Terms of Reference for External Auditors  

	1)
	Verify
that:

	a)
	Items
and amount claimed are in accordance with Annex 2 (Details on Qualifying Costs) and the terms and conditions of the offer letter (and supplemental offer letters, if any).

	b)
	Items
claimed are used for the sole purpose of the project as stated in the offer letter, unless otherwise stated.

	b)
	Items
claimed by the company are accurately recorded in all the claim forms and schedules, and in accordance with the books and records maintained by the company.

	c)
	Description
and authenticity of items claimed are valid based on review of appropriate source documents and other appropriate audit procedures.

	d)
	Claims
agree to the appropriate source documents, e.g. invoices, personnel and payroll records, etc.

	e)
	Claims
are made only upon disbursement of cash by the grant recipient, and do not include those that are purely accounting entries without cash outlays (e.g. accruals, depreciation).

	f)
	All
items claimed are incurred and paid within the qualifying period as per the terms and conditions of the offer letter (and supplemental offer letters, if any).

Exception:

For
final claims, items claimed may be paid after the qualifying period, but before date of audit report. 

	g)
	Equipment
claimed does exist through physical verification and are installed/operating during the period stipulated in the grant. 

The
procedures as listed above from (a) to (h) should cover at least 85% of the value claimed in the statement. 

	2)
	Verify
that related party claims are excluded from item categories that prohibit related party transactions

	3)
	Enquire
and report on any sale/lease/transfer/disposal of the equipment, if applicable, that is funded by EDB during the execution of the project.

	4)
	The
auditors shall highlight any going concern issues raised in the latest audit report of the company

	5)
	In
the event that there are errors and deviations found, the auditors shall report accordingly and provide details. 

Annex 8  

FORMAT FOR PROGRESS/FINAL REPORT  

        Please submit a report of 5-10 pages in length using the following format: 

Progress/Final* Report for the period            to            .

Project No.:                        Project Title:

	Principal Party:	 	Principal Investigator:
	
Secondary Party:	
 	

 
	
Project Commencement Date:	
 	
Project Completion Date:

*
Please delete accordingly 

	1
	SUMMARY OF PROJECT STATUS

	1.1
	Project
Implementation Schedule 

Please
update the project implementation schedule—planned versus actual, and indicate in the remarks column, the reasons for any deviation. 

	 
	 	Implementation Schedule

	 
	 	 
	 	 
	 	 
	 	 
	 	 
	 	 
	 	 
	 	 
	 	 
	 	 
	 	 
	 	Remarks

	Capabilities
 
	 	1999
	 	2000
	 	2001

	 
	 	Q1
	 	Q2
	 	Q3
	 	Q4
	 	Q1
	 	Q2
	 	Q3
	 	Q4
	 	Q1
	 	Q2
	 	Q3
	 	Q4

	Task A	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	• Job I	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	• Job II	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	
	 	
	 	
	 	
	 	
	 	
	 	
	 	
	 	
	 	
	 	
	 	

	{Actual Implementation}	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	
	 	
	 	
	 	
	 	
	 	
	 	
	 	
	 	
	 	
	 	
	 	

	Task B	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	• Job I	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	• Job II	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	
	 	
	 	
	 	
	 	
	 	
	 	
	 	
	 	
	 	
	 	
	 	

	{Actual Implementation}	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	
	 	
	 	
	 	
	 	
	 	
	 	
	 	
	 	
	 	
	 	
	 	

	Task C	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	• Job I	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	• Job II	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	
	 	
	 	
	 	
	 	
	 	
	 	
	 	
	 	
	 	
	 	
	 	

	{Actual Implementation}	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	
	 	
	 	
	 	
	 	
	 	
	 	
	 	
	 	
	 	
	 	
	 	

	

	original
schedule as in Letter of Offer, Annex 1 — Project Deliverable & Milestones 
	

	actual
schedule to-date 

	1.2
	Highlight
any significant findings, noteworthy developments,  milestones achieved and capability
developed in the course of the Project.

	1.3
	Comment
on the reasons for any delay/deviation from planned project schedule. 

The following are relevant only to reports for projects in progress:

	1.4
	Highlight
with reasons any change in ownership, change in principal investigator or major change in business conditions that will have an impact on the Project.

	1.5
	Highlight
any problems encountered that will impact on the future progress of the project.

	1.6
	Describe
briefly your plan of action for the next six months, including remedial actions to overcome the problems encountered
highlighted in 1.5 (if relevant). 

	2
	R&D MANPOWER STATUS  

	 
	 	 
	 	1999
	 	2000
	 	2001
	 	Total

	No. of new RSEs(1) hired (cumulative):	 	Committed(4)	 	 	 	 	 	 	 	 
	 	 	Actual	 	 	 	 	 	 	 	 
	No. of new non-RSEs(2) hired (cumulative):	 	Committed	 	 	 	 	 	 	 	 
	 	 	Actual	 	 	 	 	 	 	 	 
	No. of existing(3) RSEs (cumulative):	 	Committed	 	 	 	 	 	 	 	 
	 	 	Actual	 	 	 	 	 	 	 	 
	No. of existing non-RSEs hired (cumulative):	 	Committed	 	 	 	 	 	 	 	 
	 	 	Actual	 	 	 	 	 	 	 	 
	Name of Researchers:	 	 	 	 	 	 	 	 	 	 
	1.	 	 	 	 	 	 	 	 	 	 
	2.	 	 	 	 	 	 	 	 	 	 

	

	(1) RSE	 	:	 	Researcher with Bachelor degree and above.
	(2) Non-RSE	 	:	 	Researcher with diplomas qualification.
	(3) Existing	 	:	 	Employed by the company before commencement of Project.
	(4) Committed	 	:	 	Figures as originally stated in Letter of Offer, Annex I

	3
	CUMULATIVE R&D RESULTS  

Please provide information where applicable. This information should be cumulative. For progress reports, information should be  updatedduring every half-yearly report submission. 

	3.1
	 Capability Development  

	Year
	 	Technologies/Capabilities Developed

	1999	 	 
	2000	 	 
	2001	 	 

	3.2
	Patents and Intellectual Properties Arising from the Project  

	Patents/Intellectual Properties
	 	Date and Place Filed/Granted/Generated
	 	Status

	1. {Title} & {Patent No.}	 	 	 	 
	2. {Title} & {Patent No.}	 	 	 	 
	3. {Title} & {Patent No.}	 	 	 	 

	3.3
	Commercialization of R&D Results  

	Year
 
	 	New Products/Services Commercialized

as a result of the R&D Project
	 	Incremental Capital

Investment(5)

(S$)
	 	Type of

Activity(6)
	 	No. of New

Employment(7)

	1999	 	 	 	 	 	 	 	 
	2000	 	 	 	 	 	 	 	 
	2001	 	 	 	 	 	 	 	 

	(5)
	Additional capital investments by the Singapore office as a result of the new activities.

 
	(6)
	 Type of activity in the value chain for the new product and/or service resulting from the R&D Project. E.g. manufacturing, marketing & distribution,
technical support, sales,
etc.

 
	(7)
	 No. of new jobs created as a result of the new activities.  

	3.4
	Other Benefits to Company due to R&D Project  

	Benefits
 
	 	 
	 	1999
	 	2000
	 	2001
	 	200...
	 	200...

	Revenue(8) attributed to the R&D Project (S$)	 	Committed(4)	 	 	 	 	 	 	 	 	 	 
	 	 	Actual / Latest Forecast(9)	 	 	 	 	 	 	 	 	 	 
	Market share (%)	 	Committed	 	 	 	 	 	 	 	 	 	 
	 	 	Actual / Latest Forecast	 	 	 	 	 	 	 	 	 	 
	Value-add per worker (S$)	 	Committed	 	 	 	 	 	 	 	 	 	 
	 	 	Actual / Latest Forecast	 	 	 	 	 	 	 	 	 	 

	(8)
	Revenue from new activities generated by the R&D project and which is accrued to the Singapore office

 
	(9)
	 To provide forecast wherever data are unavailable at point of reporting  

Describe how the R&D capabilities have helped your company (as projected by company in the initial project application and replicated in the above table) to: 

	•
	increase
in market share (to provide a proper definition of the type of market that your company is competing in);

	•
	increase
in revenue;

	•
	achieve
competitive advantage;

	•
	improve
the ranking amongst competitors;

	•
	achieve
significant awards, certification, or worldwide recognition;

	•
	etc.

 

	3.5
	Other Spin-offs due to R&D Project  

Highlight other spin-offs from the R&D Project, such as licensing of technologies developed, establishment of new joint ventures, companies, etc. 

	3.6
	Potential Opportunities  

Describe how this Project has created opportunities (as projected in the initial Project application) for your company: 

	•
	in
terms of new markets or expanded markets;

	•
	potential
increase in revenue;

	•
	etc.
 

 

	4
	FUTURE PLANS (This section is only relevant for Final Reports)  

Give a brief description of: 

	•
	any
new significant R&D capabilities that your company plans to develop in the near future.

	•
	any
product/process that may be developed in the near future arising from such new R&D capabilities. 

	5
	DECLARATION  

I
declare that the information of the R&D Project as described in the above report is true and to the best of my knowledge. 

	
	 	 	 	

	Signature of Principal Investigator	 	 	 	Date
	

	
 	

 	
 	

	Signature of CEO	 	 	 	Date

Please retain all the relevant documents in this folder so as to facilitate you in filing and submitting the claims to EDB and for your future
reference.

CHECK LIST FOR SUBMISSION OF DOCUMENTS TO EDB  

Acceptance Letter  

	1.
	Have
you signed and returned the acceptance letter to EDB within 1 month from date of the offer letter? 

Interim Claims and Reports  

	1.
	Has
the Interbank Giro form been completed and submitted together with your 1st claim?

	2.
	Have
you submitted the auditor's statement, when due,?

	3.
	Have
you submitted the project progress report, when due?

	4.
	Have
you used the EDB address labels provided for mailing of the documents to EDB? 

Final Claim and Report  

	1.
	Is
the final claim submitted within 6 months from the end of the qualifying period?

	2.
	Have
you submitted the auditor's statement?

	3.
	Have
you submitted the project final report?

	4.
	Have
you used the EDB address labels provided for mailing of the documents to EDB? 

(std
/ audit) 

QuickLinks

Exhibit 10.45QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.46    
    

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.R.F §§ 200.80(B)4 AND 240.24B-2 

 
 

ROBODESIGN INTERNATIONAL    
    
    DEVELOPMENT AGREEMENT    
    

        This Development Agreement (the "Agreement") is entered into this    day of November, 2003 (the "Effective Date"), by and between RoboDesign
International, Inc., a Delaware corporation with its principal place of business located at 5920 Pasteur Court, Carlsbad, CA 92008 ("RoboDesign"), and Isis Pharmaceuticals, Inc., a
Delaware corporation with its principal place of business located at 2292 Faraday Avenue, Carlsbad, CA 92008, ("Isis"). 

R E C I T A L S  

        A.    WHEREAS,
RoboDesign has developed and is the owner of the copyrights, Patents, trademarks and other intellectual property in certain software and hardware relating to
automation motion and vision control, and certain user interfaces to facilitate user intervention with automated devices; 

        B.    WHEREAS,
Isis, through its Ibis TherapeuticsTM program, is designing a biosensor, called Triangulation Identification Genetic Evaluation of biological Risks
("TIGER") as a tool to rapidly and specifically identify and/or detect infectious agents through their unique genomic sequences; and 

        C.    WHEREAS,
Isis desires to engage RoboDesign to develop certain instrumentation and related software to automate the TIGER detection processes. 

        NOW,
THEREFORE, in consideration of the mutual promises and covenants set forth herein, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: 

A G R E E M E N T  

1.     Definitions.  

        1.1   "Affiliate" shall mean any person, joint venture, partnership, corporation, trust, unincorporated organization or other
entity which, directly or indirectly, controls, is controlled by, or is under common control with another party. 

        1.2   "End User" shall mean the ultimate user of a Tiger 2.0 Instrument in the Field. 

        1.3   "Field" shall mean [***.] 

        1.4   "Ibis Software" means the software developed by Isis (either alone or in collaboration with a third party) for use in the
Prototype and/or the Tiger 2.0 Instrument. Ibis software does not include the Work Software. 

        1.5   "Isis Technology" shall mean all Patents, copyrights, copyright applications, trade secrets, trade names, trademarks,
formulas, know-how, drawings, sketches, configurations, models, prototypes, machines, designs, software, concepts, schematics, layouts, inventions, processes, and works of authorship owned
or controlled by Isis, including without limitation, those related to the biochemical processes used in the TIGER technology and the Ibis Software. 

        1.6   "Patent" shall mean (a) patent applications (including provisional applications and applications for certificates
of invention); (b) any patents issuing from such patent applications (including certificates of invention); (c) all patents and patent applications based on, corresponding to, or
claiming the priority date(s) of any of the foregoing; and (d) any substitutions, extensions (including supplemental protection certificates), registrations, confirmations, reissues,
divisionals, continuations, continuations-in-part (but only to the extent claiming subject matter previously disclosed in the parent application), re-examinations,
renewals and foreign counterparts thereof. 

 

        1.7   "Prototype" shall mean the initial design and development of a pre-production prototype of the Tiger 2.0
Instrument, which shall include the Work Software and certain RoboDesign Software and may include the Ibis Software. After satisfactory completion of the acceptance tests specified in Sections 2.2,
2.3 and 2.4, the Prototype may be used as a Tiger 2.0 Instrument. 

        1.8   "RoboDesign Blocking Technology" shall mean all Patents, copyrights, copyright applications, trade secrets, trade names,
trademarks, formulas, know-how, drawings, sketches, configurations, models, prototypes, machines, designs, software, concepts, schematics, layouts, inventions, processes, and works of
authorship owned or controlled by RoboDesign (except for the RoboDesign Software and the RoboDesign Architecture) that are necessary to make, use or sell a Tiger 2.0 Instrument. 

        1.9   "RoboDesign Architecture" shall mean the techniques of using the RoboDesign Software to define a distributed network of
individual machine controllers as a system to support a collective process and to schedule, synchronize, configure, control and monitor the individual machines in order to complete specific process
jobs, which RoboDesign has developed, or may develop outside of its tasks under this Agreement, and which can be used, among other ways, to assist in the development of the Work Software and the
operation of the Tiger 2.0 Instrument. 

        1.10   "RoboDesign Software" shall mean software components including ActiveX controls, class and other library
modules, device drivers, and other software objects, relating to automation, motion control, vision systems, image processing, machine control, machine simulation and diagnostics, machine remoting,
synchronization and scheduling, machine data collection and visualization, data tracking, recipe and script generation and user interfaces to facilitate user intervention with automated devices, which
RoboDesign has developed, or may develop outside of its tasks under this Agreement, and which can be used, among other ways, to assist in the development of the Work Software and the operation of the
Tiger 2.0 Instrument. RoboDesign Software does not include the Work Software or the Ibis Software. 

        1.11   "Tiger 2.0 Instrument" shall mean the instrument for the automated detection of infectious agents by use
of Isis' TIGER technology, as more fully described in the Specifications attached as Exhibit B, or any successor instrument thereto that employs
[***.] 

        1.12   "Unauthorized Code" means (i) any software routine designed to disable a computer program
automatically or under the positive control of a person other than a licensee of the program and (ii) any software routines or hardware components designed to permit unauthorized access to
disable, erase, or otherwise harm software, hardware, or data. Unauthorized Code does not include software routines in a computer program, if any, designed to permit RoboDesign to obtain access to the
RoboDesign Software or the Work Software to perform its obligations under this Agreement (e.g., remote access via modem). 

        1.13   "Work" shall mean all work product, services and information, and all intellectual property rights
therein, created or developed by RoboDesign under this Agreement, including without limitation, (i) the Prototype, (ii) Patents, copyrights, copyright applications, trade secrets, trade
names, trademarks, moral rights, know-how, drawings, sketches, configurations, models, prototypes, machines, designs, computer files containing designs, concepts, schematics, layouts,
inventions, processes, ideas, improvements and works of authorship; (iii) the Work Software, including its source code and design documents, (but not the RoboDesign Software) and related
enhancements, upgrades, bug fixes and any derivative works thereof; (iv) operator, user and technical manuals relating to such software; and (v) training materials, guides,
specifications, listings and any other information concerning the Prototype. "Work" shall not include (a) the RoboDesign Architecture and the
RoboDesign Software, and (b) the Isis Technology (even if such Isis Technology is integrated with any other Work). 

2

 

        1.14   "Work Software" shall mean the software developed by RoboDesign hereunder for use in connection with the
Tiger 2.0 Instrument. Work Software does not include the RoboDesign Software or the Ibis Software. 

        1.15    Other Definitions.    The following other terms are defined as follows: 

"Effective Date" shall have the meaning set forth in the Preamble. 

"End User License shall have the meaning set forth in Section 4.3. 

"Escrow Agreement" shall have the meaning set forth in Section 4.6(a) 

"Factory Acceptance Test" shall have the meaning set forth in Section 2.2. 

"Release Event" shall have the meaning set forth in Section 4.6(b) 

"Site Acceptance Test" shall have the meaning set forth in Section 2.3. 

"Specifications" shall have the meaning set forth in Section 2.1. 

"Source Code" shall have the meaning set forth in Section 4.6(a). 

2.     Product Development.  

        2.1    Design & Development of Prototype.    RoboDesign shall use commercially reasonable efforts to design and
develop the Prototype, including the Work Software, according to design specifications provided to RoboDesign by Isis and attached as Exhibit B
(the "Specifications") within [***] months of the Effective Date. 

        2.2    Factory Acceptance Test.    Upon completion of the Prototype, RoboDesign shall conduct the testing set forth on  Exhibit C (the "Factory Acceptance Test"), it being acknowledged that the Factory Acceptance Test shall evaluate [***].
If the Prototype fails to satisfy the Factory
Acceptance Test requirements, RoboDesign shall, as soon as practicable, modify the Prototype, at [***] to Isis, and again perform the Factory Acceptance Test as needed until
the Prototype successfully meets the Factory Acceptance Test requirements. When the Prototype has successfully satisfied the Factory Acceptance Test, RoboDesign shall give Isis written notice thereof
and Isis shall take possession of the Prototype as set forth in Section 2.6 below. 

        2.3    Site Acceptance Test.    Promptly upon taking possession of the Prototype, Isis shall conduct the testing set
forth on Exhibit D (the "Site Acceptance Test"), it being acknowledged that the Site Acceptance Test shall evaluate
[***]. If the Prototype fails to satisfy the Site Acceptance Test requirements, RoboDesign shall, as soon as practicable, modify the Prototype, at [***]
to Isis, and Isis shall again perform the Site Acceptance Test as needed until the Prototype successfully meets the Site Acceptance Test Requirements. When the Prototype has successfully satisfied the
Site Acceptance Test, Isis shall give RoboDesign written notice thereof. 

        2.4    Biochemical Acceptance Test.    Promptly upon taking possession of the Prototype, Isis shall conduct the
testing set forth on Exhibit E (the "Biochemical Acceptance Test"). If the Prototype fails to satisfy the Biochemical Acceptance Test
requirements, RoboDesign shall, as soon as practicable, modify the Prototype (i) at [***] to Isis if the failure to satisfy the Biochemical Acceptance Test is due to the
Prototype's failure to meet the Specifications (as updated by mutually agreed change requests under Section 2.7 through the time of such failure) or (ii) at [***]
to the extent such modification requires new change requests under Section 2.7 to correct the failure to satisfy the Biochemical Acceptance Test, and Isis shall again perform the Biochemical
Acceptance Test as needed until the Prototype successfully meets the Biochemical Acceptance Test Requirements. When the Prototype has successfully satisfied the Biochemical Acceptance Test, Isis shall
give RoboDesign written notice thereof. 

3

 

        2.5    Development Fee Payments.    Isis agrees to pay to RoboDesign all development fees as set forth on  Exhibit F (the
"Development Fees") within [***] days of the applicable due date specified on  Exhibit F by wire transfer to a bank account designated by RoboDesign or by check payable to RoboDesign. In the event
any payment of the
Development Fees are not made when due such unpaid Development Fees shall bear interest at the rate of [***]% per month, or the maximum rate as permissible by law, whichever is
less. All Development Fees shall be non-refundable. 

        2.6    Delivery.    Following satisfactory completion of Factory Acceptance Testing, RoboDesign shall deliver the
Prototype to Isis at RoboDesign's facilities in Carlsbad, California. Title and risk of loss shall pass to Isis when Isis takes possession of the Prototype at RoboDesign's facilities. In addition to
the Prototype, RoboDesign will deliver to Isis the Work. 

        2.7    Change Requests.    In the event Isis requests modifications to the design specifications for the Prototype
which are beyond the scope of the original design specifications, RoboDesign agrees to cooperate with Isis to accommodate reasonable changes to such design specifications;  provided, however, that if any
such changes or alternative or additional design specifications require RoboDesign to invest additional resources
(including personnel resources) beyond what is contemplated by the then-current design specifications, or will result in additional costs to RoboDesign, then RoboDesign will provide a
quote for such changes and if Isis agrees, RoboDesign will undertake the changes and Isis shall pay per the quote in accordance with the terms defined in Exhibit F. If any Isis change request
will impact a delivery schedule previously agreed upon by the parties, RoboDesign shall notify Isis and the parties shall make reasonable and appropriate adjustments to such delivery schedule. 

3.     Ownership of Technology.  

        Subject to the rights set forth in Section 4 below: 

        3.1    Work for Hire.    RoboDesign hereby agrees that all Work has been specially ordered and commissioned by Isis
and shall be "works made for hire" for copyright purposes. Isis shall exclusively own all Work, including, without limitation, all Patent, trade secret and copyright rights therein. 

        3.2    Assignment.    RoboDesign hereby assigns to Isis, its successors and assigns, all rights, title and interest in
and to the Work including, without limitation, the following: 

        (a)   any
U.S. copyrights that RoboDesign may possess or acquire in the Work and all copyrights and equivalent rights in the Work throughout the world, including all renewals
and extensions of such rights that may be secured under the laws now or hereafter in force and effect in the United States of America or in any other country or countries; 

        (b)   all
rights in and to any inventions, ideas, designs, concepts, techniques, discoveries, or improvements, whether or not patentable, embodied in the Work or developed in
the course of RoboDesign's creation of the Work, including, but not limited to, all trade secrets, utility and design Patent rights and equivalent rights in and to such inventions and designs
throughout the world, regardless of whether or not legal protection for the Work is sought; 

        (c)   any
documents, drawings, magnetically or optically encoded media, or other materials created by RoboDesign under this Agreement; and 

        (d)   the
right to sue for infringements, which may occur before the date of this Agreement, and to collect and retain damages from any such infringements. 

        3.3    Further Assistance.    At Isis' expense, RoboDesign shall take all actions and execute and deliver all
documents as Isis may reasonably request to effectuate the acknowledgement of ownership herein and vesting of complete and exclusive ownership of the Work in Isis. RoboDesign will provide reasonable
assistance to Isis and its attorneys and agents in securing any of the patent or other proprietary rights provided for in this Section 3.3, including to effectuate the acknowledgement of 

4

 

ownership
contained herein and the vesting of complete and exclusive ownership of the Work in Isis, and to secure, maintain and defend for Isis' own benefit all rights therein, including the right to
submit any Patent, copyright or trademark application or registration. 

        3.4    Isis Technology.    RoboDesign shall have no right, title or interest in or to the Isis Technology. 

4.     Licenses.  

        4.1    Grant-Back of License in the Work by Isis.    Isis hereby grants to RoboDesign an irrevocable,
perpetual, worldwide, royalty-free, non-exclusive, transferable and assignable license, with the right to sublicense, solely to use, modify, copy, incorporate, create
derivative works from, manufacture and have manufactured products incorporating the Work for applications outside the Field. 

        4.2    Grant of License in the Isis Technology by Isis.    During the term of this Agreement, Isis hereby grants to
RoboDesign a, nonexclusive, nonassignable, nontransferable royalty-free license to use, modify, copy, incorporate, create derivative works from the Isis Technology solely for the purpose
of performing RoboDesign's obligations under this Agreement. 

        4.3    Software License by RoboDesign.    RoboDesign hereby grants to Isis (i) a non-exclusive,
limited license to deliver one (1) copy of the RoboDesign Software (in binary executable form) together with a Tiger 2.0 Instrument to an End User, (ii) a limited right to grant a
sublicense to each End User to use one (1) copy of the RoboDesign Software in conjunction with each Tiger 2.0 Instrument only, provided that such sublicense is granted pursuant to an end user
license agreement (the "End User License Agreement") with terms no less protective of RoboDesign's rights than those set forth on  Exhibit G hereto. The license rights granted under clauses
(i) and (ii) of this Section 4.3 are sublicensable, transferrable
and/or assignable only to (x) the United States government, (y) a partner of Isis that has agreed to make or commercialize a Tiger 2.0 Instrument, or (z) as permitted under
Section 10.9. 

        4.4    Unblocking License by RoboDesign.    RoboDesign hereby grants to Isis a non-exclusive, license to
practice the RoboDesign Blocking Technology and the RoboDesign Architecture solely to the extent necessary to make, use or sell a Tiger 2.0 Instrument in the Field. This license is sublicensable to
End Users and the United States government, and is assignable to a partner of Isis that has agreed to make or commercialize a Tiger 2.0 Instrument or as permitted under Section 10.9. 

        4.5    Government Rights.    The licenses granted under this Section 4.1and 4.2 are subject to the rights of
the United States Government as set forth in 35 U.S.C. § 200 et seq. If there is any conflict between such rights and the rights granted
herein, such government rights will prevail. 

        4.6    Source Code Escrow.    

        (a)   Escrow Agreement. If requested by Isis in writing, within 30 days of such request RoboDesign will deliver one
(1) copy of the RoboDesign Software incorporated in the Tiger 2.0 Instrument in source code form (the "Source Code") along with documentation as to the applicable use of the RoboDesign
Architecture, to an escrow agent to be mutually determined by the parties (the "Escrow Agent"), and at such time, RoboDesign, Isis and the Escrow Agent shall enter into the Escrow Agreement (the
"Escrow Agreement"), which shall, among other things, reflect the terms set forth in this Section 4.6. All fees and expenses charged by the Escrow Agent will be borne by Isis. 

        (b)   Release Events for Source Code. The Source Code and related documentation shall be released from escrow and delivered to
Isis upon the occurrence of one or more of the following events (each, a "Release Event"): (I) if RoboDesign becomes insolvent or admits insolvency or admits a general inability to pay its
debts as they become due; (II) if RoboDesign files a petition 

5

 

for
protection under the Bankruptcy Code of the United States, or an involuntary petition in bankruptcy is filed against RoboDesign and is not dismissed within sixty (60) days thereafter;
(III) if RoboDesign or its successor with respect to this Agreement ceases operations as a going concern or (IV) RoboDesign refuses to or is unable to honor the warranty set forth in
Section 5.1 or provide post warranty service under Section 5.2. 

        (c)   Effect of Release Event. Upon the occurrence of a Release Event and the delivery of the Source Code and related
documentation to Isis, Isis shall have right only to use the Source Code and related documentation to maintain and upgrade the software in the Tiger 2.0 Instrument (including those being
used by End Users) in accordance with the scope of the License set forth in Section 4.3 and shall have no right to use the RoboDesign Software, the Source Code or related documentation to
design, develop, use or market any other products. All right, title and interest in and to the Source Code and all related documentation, and all copyrights, Patents, trademarks, service marks or
other intellectual property or proprietary rights related thereto are and shall remain solely with RoboDesign, both prior to and after the occurrence of the Release Event. Isis acknowledges that no
other right, title or interest in or to the Source Code or related documentation is granted under this Agreement, and that no such assertion shall be made by Isis either prior to or after the
occurrence of the Release Event. Isis shall treat the Source Code and the related documentation as Proprietary Information pursuant to Article 7 below. 

5.     Warranties, Indemnity, Limitations of Liability, Insurance  

        5.1    Limited Warranty, Warranty Service.    

        (a)   RoboDesign
expressly warrants to Isis that the Prototype shall conform with the Specifications and be free from defects in materials and workmanship for a period of
[***] months following the date the Prototype satisfactorily completes the Site Acceptance Test (the "Warranty Period"), it being acknowledged that such warranty covers only
the electromechanical operation of the Prototype and not the efficacy of the biochemical tests performed by the Prototype. The terms of Exhibit H
shall apply to RoboDesign's warranty hereunder. RoboDesign's liability under this warranty shall be limited, at its option, to replacing or repairing Prototype shown to be defective in materials or
workmanship. A claim of defective materials or workmanship in the Prototype shall be allowed only when it is submitted to RoboDesign in writing within [***] days after
discovery by Isis or the End User of the defect, and in any event, within the Warranty Period. 

        (b)   To
the best of its knowledge, RoboDesign represents and warrants to Isis that the RoboDesign Software and the Work Software provided to Isis by RoboDesign under this
Agreement does not contain or will not contain any Unauthorized Code. If RoboDesign discovers (whether on its own or through notice) any Unauthorized Code in the RoboDesign Software or Work Software
provided to Isis under this Agreement, RoboDesign will promptly remove such Unauthorized Code. 

        5.2    Post Warranty Period Service.    At Isis' option, RoboDesign shall provide service on the Prototype after the
Warranty Period on terms set forth on Exhibit H. 

        5.3    Assignment of Warranties.    If material incorporated in the Prototype contains one or more manufacturer's or
supplier's warranties, RoboDesign hereby assigns such warranties to Isis to the extent such warranties are assignable. RoboDesign will use commercially reasonable efforts to secure the ability to
assign such warranties to Isis. RoboDesign will cooperate with Isis to enable Isis to benefit from any such warranties that are not assignable. Upon Isis' request, RoboDesign will provide to Isis a
copy of such warranties. Isis may transfer or assign the warranty under Section 5.1 to an End User. 

6

 

        5.4    Intellectual Property Warranty.    RoboDesign represents and warrants that to its knowledge none of the devices
and methods included in the Prototype, when delivered to Isis under Section 2.6, will infringe any intellectual property rights in the United States of any third party. 

        5.5    No Other Warranties.    EXCEPT FOR THE EXPRESS WARRANTIES CONTAINED HEREIN, ROBODESIGN MAKES NO WARRANTY
HEREUNDER OF ANY KIND WHATSOEVER, EXPRESS OR IMPLIED, AND ALL WARRANTIES OF MERCHANTABILITY, NONINFRINGEMENT AND FITNESS FOR A PARTICULAR PURPOSE ARE HEREBY DISCLAIMED BY ROBODESIGN. 

        5.6    Indemnity by Isis.    Isis shall indemnify and hold RoboDesign harmless from and against any liability, losses,
damages, claims, costs and expenses (including reasonable fees of attorneys and other professionals and court costs) arising from any claim, action or cause of action related to the use, manufacture,
marketing or sale of Tiger 2.0 Instruments (including the Prototype), unless such claim relates to (i) infringement of third party intellectual property which was known to RoboDesign prior to,
or during its conduct of the Work or (ii) infringement of third party intellectual property through the use of the RoboDesign Software as permitted under this Agreement. Subject to the terms
and conditions of this Agreement, Isis shall have the primary responsibility for defending against any such claims, whether arising under theories of negligence, strict liability, tort, product
liability of otherwise. 

        5.7    Indemnity by RoboDesign.    RoboDesign shall indemnify and hold Isis harmless from and against any liability,
losses, damages, claims, costs and expenses (including reasonable fees of attorneys and other professionals and court costs) arising from (A) RoboDesign's breach of Section 5.1(b), or
(B) a claim, action or cause of action alleging that (i) the use of Tiger 2.0 Instruments (in the form of the Prototype that has successfully completed the Site Acceptance Test),
infringes a third party's intellectual property which was known to RoboDesign prior to, or during its conduct of the Work, or (ii) the use of RoboDesign Software as permitted under this
Agreement, infringes a third party's intellectual property; provided, however, that RoboDesign will have no liability under this clause (ii) for
any alleged infringement to the extent arising from (y) any modification of the RoboDesign Software by Isis or an End User or (z) the use of the RoboDesign Software in combination with
technology provided by Isis. Subject to the terms and conditions of this Agreement, RoboDesign shall have the primary responsibility for defending against any such claims. 

        5.8    Indemnity Procedures.    Each Party's agreement to indemnify and hold the other harmless is conditioned upon
the indemnified Party (i) providing written notice to the indemnifying Party of any claim, demand or action arising out of the indemnified activities within [***] days
after the indemnified Party has knowledge of such claim, demand or action, (ii) permitting the indemnifying Party to assume full responsibility to investigate, prepare for and defend against
any such claim or demand, (iii) assisting the indemnifying Party, at the indemnifying Party's reasonable expense, in the investigation of, preparation of and defense of any such claim or
demand; and (iv) not compromising or settling such claim or demand without the indemnifying Party's prior written consent. 

        5.9    Limitation of Liability.    IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER FOR LOSS OF PROFITS OR
SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES REGARDLESS OF WHETHER SUCH PARTY WAS ADVISED, HAD OTHER REASON TO KNOW OR IN FACT KNEW OF THE POSSIBILITY. 

        5.10    Insurance.    For so long as any Tiger 2.0 products are in use and for [***] years
following the discontinuation of such use, Isis shall at its own cost and expense, obtain and maintain in full force and effect, commercial, general liability insurance, including personal injury and
products liability coverage or require its commercialization partners to obtain and maintain such insurance. If required, Isis will provide RoboDesign with a certificate of insurance evidencing the
above and showing the name of the issuing company, the policy number, the effective date, the expiration date and the limits of liability. Isis will provide RoboDesign with written notice before Isis
cancels such insurance. 

7

 

6.     Term; Termination.  

        6.1    Term of Agreement.    The term of this Agreement shall commence on the date hereof and continue until
successful completion of the Site Acceptance Test, unless canceled or terminated earlier in accordance with the provisions of this Agreement. 

        6.2    Default Termination.    In the event of a material default under this Agreement by either party, which breach
is not cured within [***] days (or [***] days in the event of a payment default) after the defaulting party's receipt of written notice thereof, the
nondefaulting party shall be entitled to terminate this Agreement,
effective at the end of such cure period; provided, however that, once a Prototype has been delivered under Section 2.6, RoboDesign may not
terminate the licenses granted under Sections 4.3 and 4.4 for a material breach (except for a breach of Section 2.5) to the extent such licenses are necessary to make, use and sell a Tiger 2.0
Instrument. Notwithstanding anything to the contrary stated hereinabove, in addition to and in lieu of its rights to terminate this Agreement upon a material breach by either party, the other party
shall have the right to pursue any remedies available to it at law or in equity. 

        6.3    Termination for Failure.    If (A) RoboDesign fails to deliver to Isis a Prototype that meets the
material requirements of the Specifications after (i) the delivery schedule set forth in Section 2.1 lapses (as may be extended from time to time pursuant to Section 2.7) and
(ii) [***] days from the date Isis provides RoboDesign with a reasonably detailed written notice of why the Prototype does not meet the material requirements of the
Specifications, (B) and such failure results because RoboDesign did not use commercially reasonable efforts to satisfy its obligations under this Agreement, then Isis may, at its option,
terminate this Agreement by providing RoboDesign with written notice thereof and returning to RoboDesign all Work and equipment purchased by RoboDesign and provided to Isis hereunder. In such event,
(i) Robodesign will return to Isis (i) all equipment and materials provided by Isis to RoboDesign hereunder and all payments made to Robodesign under this Agreement and (ii) any
accrued payment obligations under this Agreement will terminate and not survive within 60 days of such termination. 

        6.4    Insolvency Termination.    In the event either party shall go into liquidation, or have a receiver or trustee
appointed for its property or estate, or shall make an assignment for the benefit of creditors, whether any of the aforesaid events be the outcome of a voluntary act or otherwise, the other party
shall be entitled by notice to terminate this Agreement forthwith. 

        6.5    Termination by Isis for Convenience.    Isis may terminate this Agreement at any time upon thirty
(30) days notice to RoboDesign. In such event Isis will pay RoboDesign for the services it provided through the date of such termination on a time and materials basis at the rates set forth on
Exhibit F hereto and RoboDesign will refund to Isis the amount of any funds already paid to RoboDesign that may exceed the amount owing for the time and materials. 

        6.6    Continuing Obligations.    Sections 3, 4.1, 4.5, 4.6, 5, 6, 7, 8, 9 and 10 shall survive the termination
or expiration of this Agreement. Sections 4.3 and 4.4 shall survive the expiration or termination of this Agreement only if pursuant to Section 6.1, Section 6.2 because of
material breach by RoboDesign, Section 6.4 because of insolvency of RoboDesign, or as specified in Section 6.2. Any sublicense or assignment of warranty granted by Isis to an End User
under Section 4.3 will survive termination of this Agreement. 

7.     Confidential Information.  

        7.1   Both
RoboDesign and Isis have made and will continue throughout the term of this Agreement to make available to the other party its confidential and proprietary
materials and information ("Proprietary Information"). All material and information provided by one party to the other party relating to the business, policies, procedures, customs and forms of
providing party or any 

8

 

of
its Affiliates (including, without limitation, the RoboDesign Technology, the Isis Technology, and the Prototype) as well as information previously divulged or delivered regarding the
aforementioned subject matter, is hereby designated as confidential and proprietary and shall be considered to be Proprietary Information of the disclosing party. It is understood that the obligations
set forth above in this Section 7.1 do not apply to materials or information that: (a) are already, or otherwise become, generally known by third parties, except as a result of a
wrongful act or omission of the receiving party; (b) are generally furnished to others by the disclosing party without restriction on disclosure; (c) were already known by the receiving
party prior to receiving them from the disclosing party and were not received from a third party in breach of that third party's obligations of confidentiality; or (d) are independently
developed by the receiving party without the use of Proprietary Information of the disclosing party. 

        7.2   The
receiving party shall maintain the confidentiality of the disclosing party's Proprietary Information, will not disclose such Proprietary Information without the
prior written consent of the disclosing party, and will use such Proprietary Information solely to perform its obligations hereunder. Each party shall also keep confidential the terms of this
Agreement and/or any Exhibit hereto, except that either party may disclose such terms to its legal, accounting or financial advisors. 

        7.3   Neither
party's obligations of confidentiality will prevent or prohibit the parties from providing access to Proprietary Information upon request of a state or federal
regulatory agency or authority as may be required by law or judicial or administrative process. Notwithstanding the foregoing, in the event of any requested access to Proprietary Information by a
regulatory authority, the party from whom the Proprietary Information is requested will provide written notice to the other party in a timely fashion to allow the other party the opportunity to
contest the release of its Proprietary Information to such regulatory authority. 

        7.4   RoboDesign
will not disclose the terms or existence of this Agreement without the prior written consent of Isis unless such disclosure is made pursuant to a confidential
disclosure agreement with terms substantially similar to those contained in Sections 7.1 through 7.3. 

        8.     Noncompetition. During the term of this Agreement and for [***]years thereafter, RoboDesign will
not develop or commercialize, or assist in the development or commercialization of [***]. 

        9.     Export Compliance. Unless an appropriate license, exemption, or similar authorization has been duly obtained, Isis shall
not, nor shall Isis authorize its employees, distributors, customers, and/or agents to, export or re-export the Prototype or a Tiger 2.0 Instrument (including any information relating
thereto) to any country specified as a prohibited destination in applicable U.S. laws, regulations, and ordinances, including the Regulations of the U.S. Department of Commerce and/or other government
agencies. Isis agrees to defend, indemnify, and hold harmless RoboDesign from and against any claim, loss, liability, expense, or damage (including liens or legal fees) incurred by RoboDesign with
respect to any of Isis' export or re-export activities contrary to the foregoing instructions (subject to the procedures set forth in Section 5.8). 

10.   Miscellaneous.  

        10.1    ISO 9001.    RoboDesign represents and warrants that it will maintain at its sole expense its ISO 9001
or ISO 9002 certifications and will apply an ISO 9001 and/or ISO 9002 (as applicable) compliant quality system to the design and manufacture of the Prototype. 

        10.2    Force Majeure.    Neither party shall be liable for failures or delays (not to exceed
[***] months) in performance hereunder due to fire, explosion, breakdown of plant, lockout, casualty or accident, acts of God or the public enemy, interference by civil or
military authority, compliance with 

9

 

applicable
laws of the United States of America or of any other governmental authority, or any other similar cause beyond the control of the party in question. 

        10.3    Construction; Interpretation.    The headings contained in this Agreement are for reference purposes only and
shall not affect in any way the meaning or interpretation of this Agreement. Any article, section, recital, exhibit, schedule and party references are to this Agreement unless otherwise stated. No
party, nor its counsel, shall be deemed the drafter of this Agreement for purposes of construing the provisions of this Agreement, and all provisions of this Agreement shall be construed in accordance
with their fair meaning, and not strictly for or against any party. 

        10.4    Notices.    Any notice, demand, approval, consent, or other communication required or desired to be given
under this Agreement shall be in writing and shall be (i) personally served, (ii) mailed in the United States mail, certified, return receipt requested, postage prepaid, or
(iii) sent via commercial overnight courier, in each case addressed to the party to be served with the copies indicated below, at the last address given by that party to the other under the
provisions of this section. All such
communications shall be deemed delivered at the earlier of actual receipt or (i) three (3) business days following mailing by U.S. mail or (ii) one (1) business day
following deposit with a commercial overnight courier. 

	 	 	RoboDesign:	 	RoboDesign International, Inc.

5920 Pasteur Court

Carlsbad, CA 92008

Attn: Chief Executive Officer
	

 	
 	

With a copy to:	
 	

Stradling Yocca Carlson & Rauth

660 Newport Center Drive, Suite 1600

Newport Beach, California 92660

Attn: Lawrence B. Cohn
	

 	
 	

Isis:	
 	

Isis Pharmaceuticals, Inc.

2292 Faraday Avenue

Carlsbad CA 92008

Attn: David J. Ecker, Ph.D.
	

 	
 	

With a copy to:	
 	

Isis Pharmaceuticals, Inc.

2292 Faraday Avenue

Carlsbad CA 92008

Attn: General Counsel

        10.5    Further Assurances.    Each party agrees to cooperate fully with the other and execute such instruments,
documents and agreements and take such further actions to carry out the intents and purposes of this Agreement. 

        10.6    Severability.    If any term, provision, covenant or condition of this Agreement is found by a court of
competent jurisdiction to be invalid, void or unenforceable, then such term, provision, covenant or condition shall be deemed to be stricken from this Agreement and the remainder of this Agreement
shall remain in full force and effect and shall in no way be effected, impaired or invalidated thereby. 

        10.7    Governing Law; Arbitration.    This Agreement shall be governed by, and construed in accordance with the laws
of the State of California, without reference to rules of conflict or choice of laws that could result in the application of laws of another jurisdiction. All disputes, differences or questions
arising out of this Agreement or as to the rights or obligations of the parties hereunder or in connection herewith or as to the construction or interpretation hereof shall be attempted to be resolved 

10

 

by
discussion between the CEO of RoboDesign and the Executive Vice President of Isis. Any such disputes which cannot be so resolved within thirty (30) days of written notification to the CEO of
RoboDesign and the CEO of Isis detailing the nature of the dispute(s) shall be referred to binding arbitration, held in San Diego, California, before a single arbitrator in accordance with the
Commercial Arbitration Rules of the American Arbitration Association. 

        10.8    Independent Contractor Status, No Agency.    RoboDesign's and Isis' activities hereunder shall be conducted as
independent contractors and no agency relationship shall exist between the parties. Neither party shall represent to any third party that it is an agent or Affiliate of the other party. 

        10.9    Assignment.    This Agreement shall not be assignable by either party without the consent of the other party,
which shall not be unreasonably withheld. Notwithstanding the foregoing, either party may, without the other's consent, assign or otherwise transfer this Agreement or any right or obligation hereunder
to any affiliate or in connection with the transfer or sale of the business (whether by merger, sale of stock or sale of assets) to which this Agreement relates. All the terms, covenants and
conditions of this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns. 

        10.10    Parties in Interest.    Nothing in this Agreement, whether express or implied, is intended to confer any
rights or remedies under or by reason of this Agreement on any persons other than the parties to it and their respective successors, permitted sublicensees and assigns, nor is anything in this
Agreement intended to relieve or discharge the obligation or liability of any third persons to any party to this Agreement, nor shall any provision give any third persons any right of subrogation or
action over or against any party to this Agreement. 

        10.11    Counterparts.    This Agreement may be executed in two or more counterparts, each of which shall be deemed an
original and all of which, taken together, shall constitute one instrument. 

        10.12    Entire Agreement; Amendment.    This Agreement (including all Exhibits hereto) sets forth the entire
understanding and agreement between the parties with respect to the subject matter hereof, and supersedes and replaces any prior understanding, agreement or statement, written or oral, with respect to
the same. Any terms of any purchase order, confirmation or invoice, whether or not signed, are
expressly rejected and shall be superseded by this Agreement. The parties hereto expressly agree and confirm that this Agreement is executed without reliance on any oral or written statements,
representations or promises of any kind which are not expressly contained in this Agreement. This Agreement, and the Exhibits hereto, shall not be modified except by a writing signed on behalf of each
of the parties hereto. 

        IN
WITNESS WHEREOF, the parties have executed this Development Agreement as of the Effective Date. 

	 	 	"RoboDesign"
	

 	
 	

ROBODESIGN INTERNATIONAL, INC.,

a Delaware corporation
	

 	
 	

By:	

/s/  ROBERT COREY      

	 	 	Its:	CEO

	

 	
 	

"Isis"
	

 	
 	

ISIS PHARMACEUTICALS, INC.,

a Delaware corporation
	

 	
 	

By:	

/s/  B. LYNNE PARSHALL      

	 	 	Its:	EVP and CFO

11

   EXHIBIT B  

 SPECIFICATIONS  

 [***]  

        Specifications include Developer Kit to allow Isis to modify system protocols,

control logic and parameters independently of RoboDesign

12

   EXHIBIT C  

 FACTORY ACCEPTANCE TEST  

        The specifics of the Factory Acceptance Test will be agreed upon

by the Parties within 30 days of the Effective Date

13

   EXHIBIT D  

 SITE ACCEPTANCE TEST  

        The specifics of the Site Acceptance Test will be agreed upon

by the Parties within 30 days of the Effective Date

14

   EXHIBIT E  

 BIOCHEMICAL ACCEPTANCE TEST  

        The specifics of the Biochemical Acceptance Test will be agreed upon

by the Parties within 30 days of the Effective Date

15

   EXHIBIT F  

 DEVELOPMENT FEES  

 Development Fees  

[***] 

 Payment Schedule  

[***]payable
on Effective Date 

[***]
payable [***] days from Effective Date 

[***]
payable on successful completion of Factory Acceptance Test 

[***]
payable on successful completion of Site Acceptance Test, provided, however that if Isis fails to complete the Site Acceptance Test within [***]
days following successful completion of the Factory Acceptance Test, the aforementioned [***] shall be due and payable by Isis at the end of such [***]
days. 

[***]
payable on successful completion of Biochemical Acceptance Test, provided, however that if Isis fails to complete the Biochemical Acceptance Test within
[***] days following its payment of the [***] set forth above, the remaining [***] shall be due and payable by Isis at the end
of such [***] days. 

Design
Changes: 

RoboDesign
may at its (i) option bill [***] of the incremental cost attributable to such design change upon acceptance of change order by Isis and
[***] upon completion and acceptance of such design change, due upon receipt of invoice; or (ii) Bill for Isis approved changes upon completion, due upon receipt of
invoice. 

Purchase Price of Developer Kit (as described in the Specifications): [***] 

16

   TIME & MATERIALS PRICING  

        Senior Management—[***] per hour 

        Project
Management—[***] per hour 

        Software
Engineer—[***] per hour 

        Mechanical &
Electrical Engineer—[***] per hour 

        Field
Service Technicians—[***] 

        All
other employees—[***] per hour 

        Materials—Priced
at a Prime Profit rate of [***]. 

17

   EXHIBIT G  

 MINIMUM END USER LICENSE  

Important—read carefully: this document is a legal agreement between you, the Licensee, and Isis Pharmaceuticals, the Licensor, for this software product. By
installing or otherwise using the software product, you agree to be bound by the terms of this agreement.

        1.    GRANT OF LICENSE.    In consideration of payment of the license fee, which is part of the price paid for this
product, Licensor grants to the Licensee a non-exclusive, non-transferable license, without right to sublicense, to use this copy of the enclosed software on the single
computer in conjunction with the equipment on which it was provided at a single location. Licensor reserves all rights not expressly granted to Licensee. 

        2.    OWNERSHIP OF SOFTWARE.    As between Licensee and Licensor, title to, ownership of, and all rights and interests
in, the software and software documentation, and all copies thereof remains at all times vested in Licensor. The license granted by this Agreement and your payment of the license fee gives you the
right to use the software in accordance with the terms of this Agreement. This license is not a sale of the original software or any copy. 

        3.    COPY RESTRICTIONS.    This software and the accompanying written materials are copyrighted. Unauthorized copying
of the software, including software that has been modified, merged, or included with other software, or other written materials is expressly forbidden. You may be held legally responsible for any
copyright infringement that is caused or incurred by your failure to abide by the terms of this license. Subject to these restrictions, you may make one (1) archival copy of the software solely
for backup purposes as permitted by 17 U.S.C. § 117. You must reproduce and include the original copyright notice with the copy. This clause does not provide any rights beyond those
provided by 17 U.S.C. § 117. 

        4.    USE RESTRICTIONS.    As the Licensee, you may not electronically transfer the software from one computer to
another over a network. You may not disclose, publish, translate, release, or distribute copies of the software or accompanying written materials to others. You may not modify, adapt, translate, or
create derivative works based on the written materials without the prior written consent of Licensor. You may not loan, rent, lease, sell or transfer the software to another user except as part of the
permanent transfer of all software, written materials and hardware with which the software was delivered. 

        5.    TERMINATION.    This license is effective until terminated. This license will terminate automatically without
notice if you fail to comply with any provision of this license. Upon termination you shall destroy the written materials and all copies of the software, including modified copies, if any. 

        6.    LIMITED WARRANTY.    Licensor warrants to the original media on which the software is (are) recorded is (are)
free from defects and materials and workmanship under normal use and service for a period of ninety (90) days from the date of delivery as evidenced by a copy of the sales receipt. Further,
Licensor hereby limits the duration of any implied warranty(ies) on the media to the period stated above. Some states do not allow limitations on duration of an implied warranty, so the above
limitation may not apply to you. 

        7.    DISCLAIMER OF WARRANTY AND LIMITED WARRANTY.    The software and accompanying written
materials, including instructions for use, are provided "as is" without warranty of any kind, either express or implied. Further, Licensor does not warrant, guarantee, or make any representations
regarding the use, or the results of the use, of the software or written materials in terms of accuracy, reliability, currentness, or otherwise. The entire risk as to the results and performance of
the software is assumed by you. If the software or written materials are defective, the Licensor or its dealers, distributors, agents, or employees, are not responsible for the cost of any  

18

 

 necessary servicing, repair, or correction. Licensor's entire liability and your exclusive remedy as to the media will be, at Licensor's option, either (a) return of the purchase price or
(b) replacement of the media that does not meet limited warranty and which is returned to Licensor with a copy of the sales receipt. If failure of the media has resulted from accident, abuse,
or misapplication, Licensor shall have no responsibility to replace the disk or refund the purchase price. Any replacement media is warranted for the remainder of the original warranty period or
thirty (30) days, whichever is longer.

Except as stated above the software provided and the documentation are provided without warranties of any kind, either express or implied, including but not limited to the
implied warranties of non-infringement, merchantability and fitness for a particular purpose. No oral or written information or advice given Licensor its dealers, distributors, agents, or
employees shall create a warranty or in any way increase the scope of this warrant, and you may not rely on any such information or advice. This warranty gives you specific legal rights. You may have
other rights, which vary from state to state.  

Neither Licensor nor anyone else who has been involved in the creation, production, or delivery of this product shall be liable for any direct,
indirect, consequential, or incidental damages, including damages for loss of business profits, business interruption, loss of business information, and the like (arising out of the use of or
inability to use such products) even if Licensor has been advised of the possibility of such damages. Because some states do not allow the exclusion or limitation of liability for consequential or
incidental damages, the above limitation may not apply to you.  

        8.    MISCELLANEOUS.    This Agreement expresses the entire agreement between Licensor and the
LICENSEE and supersedes any prior communications, oral or written relating to this software. This Agreement is governed by the laws of the State of California 

        9.    U.S. GOVERNMENT RESTRICTED RIGHTS.    The software and documentation is provided with RESTRICTED RIGHTS. Use,
duplication, or disclosure by the Government is subject to restrictions as set forth in subparagraph (c)(1)(ii) of the Rights in Technical Data and Computer Software clause at DFARS
252.227-7013. Contractor/manufacturer is                        , located
at                                         
       . Should you have any questions concerning this Agreement, or if you desire to contact Licensor, please
write to:                        , located
at                        . 

19

   EXHIBIT H  

 STANDARD WARRANTY TERMS  

RoboDesign
provides a limited warranty as standard with all of its products. During the coverage term, technical support as well as software upgrades are provided free of charge. This will allow our
service engineers to quickly address any initial problems thus ensuring accurate and reliable system performance. 

Warranty Features  

	•	 	Coverage Terms
	 	 	[***] month for parts and labor. Unlimited technical support via phone or email. 1-2 business hour response and on-site support while the prototype system is located in the San Diego area.
	

•	
 	
Software
	 	 	All software updates and upgrades, as released during the term. Includes updated manuals and other support documentation.
	

•	
 	
On-site Emergency Visits
	

 	
 	

Unlimited as needed.

	Summary of Services
	Period of Service Coverage	 	Monday-Saturday, 8am-5pm excluding holidays, or as needed for emergency visits
	Parts	 	Included for [***] months
	Labor	 	Included for [***] months
	Telephone and Email Response	 	1-2 business hours
	Emergency Visits	 	As needed
	Emergency Visit Response	 	Same day while prototype system is located in San Diego, 2-3 business day if elsewhere
	Preventative Maintenance Visits	 	As needed
	Travel Expenses	 	Included
	Software Revisions and Upgrades	 	Included
	Training	 	As needed

20

QuickLinks

Exhibit 10.46

ROBODESIGN INTERNATIONAL DEVELOPMENT AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00062-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00062-of-00352.parquet"}]]